EUR 0.07
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 19.79 Thousand EUR | -99.21% |
2022 | 2.51 Million EUR | -19.85% |
2021 | 3.13 Million EUR | 71.57% |
2020 | 1.82 Million EUR | 18.23% |
2019 | 1.54 Million EUR | 41869.61% |
2018 | 3686.00 EUR | 0.0% |
2017 | - EUR | 0.0% |
2016 | - EUR | -100.0% |
2015 | 144.13 Thousand EUR | -55.55% |
2014 | 324.3 Thousand EUR | 1763.82% |
2013 | 17.4 Thousand EUR | -9.38% |
2012 | 19.2 Thousand EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - EUR | 0.0% |
2023 Q4 | 12.00 EUR | 0.0% |
2023 FY | 10.06 Thousand EUR | -99.6% |
2023 Q2 | 10.06 Thousand EUR | 0.0% |
2022 Q4 | 131.00 EUR | 0.0% |
2022 Q2 | 897 Thousand EUR | 0.0% |
2022 FY | 2.51 Million EUR | -19.85% |
2021 FY | 3.13 Million EUR | 71.57% |
2021 Q4 | 3.43 Million EUR | 0.0% |
2021 Q2 | 101.63 Thousand EUR | 0.0% |
2020 FY | 1.82 Million EUR | 18.23% |
2020 Q2 | 14.8 Thousand EUR | 0.0% |
2020 Q4 | 3.96 Million EUR | 0.0% |
2019 FY | 1.54 Million EUR | 41869.61% |
2019 Q2 | 5591.00 EUR | 0.0% |
2019 Q4 | 4424.00 EUR | 0.0% |
2018 Q4 | 3686.00 EUR | 0.0% |
2018 FY | 3686.00 EUR | 0.0% |
2018 Q2 | - EUR | 0.0% |
2017 Q2 | 1.00 EUR | 0.0% |
2017 FY | - EUR | 0.0% |
2017 Q4 | -1.00 EUR | 0.0% |
2016 FY | - EUR | -100.0% |
2016 Q4 | -1.00 EUR | 0.0% |
2016 Q2 | 1.00 EUR | 0.0% |
2015 Q4 | 6298.00 EUR | 0.0% |
2015 FY | 144.13 Thousand EUR | -55.55% |
2015 Q2 | 137.84 Thousand EUR | 0.0% |
2014 Q2 | 80.01 Thousand EUR | 0.0% |
2014 Q4 | 244.29 Thousand EUR | 0.0% |
2014 FY | 324.3 Thousand EUR | 1763.82% |
2013 Q3 | 4350.00 EUR | -54.69% |
2013 Q1 | 4350.00 EUR | 0.0% |
2013 Q2 | 9600.00 EUR | 120.69% |
2013 Q4 | 12.32 Thousand EUR | 183.33% |
2013 FY | 17.4 Thousand EUR | -9.38% |
2012 Q3 | 4800.00 EUR | 0.0% |
2012 Q1 | 4800.00 EUR | 0.0% |
2012 FY | 19.2 Thousand EUR | 0.0% |
2012 Q4 | 4350.00 EUR | -9.38% |
2012 Q2 | 4800.00 EUR | 0.0% |
2011 Q4 | 4800.00 EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ABIONYX Pharma SA | 4.64 Million EUR | 99.573% |
ABIVAX Société Anonyme | 4.62 Million EUR | 99.572% |
Adocia SA | 2.15 Million EUR | 99.079% |
Aelis Farma SA | 9.05 Million EUR | 99.781% |
Biophytis S.A. | - EUR | -Infinity% |
Advicenne S.A. | 3.15 Million EUR | 99.372% |
genOway Société anonyme | 20.04 Million EUR | 99.901% |
IntegraGen SA | 12.53 Million EUR | 99.842% |
Medesis Pharma S.A. | 300.03 Thousand EUR | 93.402% |
Neovacs S.A. | 533.41 Thousand EUR | 96.289% |
NFL Biosciences SA | - EUR | -Infinity% |
Plant Advanced Technologies SA | 1.68 Million EUR | 98.823% |
Sensorion SA | 4.74 Million EUR | 99.583% |
Theranexus Société Anonyme | 296.33 Thousand EUR | 93.32% |
TME Pharma N.V. | 17 Thousand EUR | -16.447% |
Valbiotis SA | 4.73 Million EUR | 99.582% |
TheraVet SA | 1.07 Million EUR | 98.164% |
Valerio Therapeutics Société anonyme | 1.8 Million EUR | 98.9% |
argenx SE | 1.13 Billion EUR | 99.998% |
BioSenic S.A. | 543 Thousand EUR | 96.354% |
Celyad Oncology SA | 102 Thousand EUR | 80.592% |
DBV Technologies S.A. | - EUR | -Infinity% |
Galapagos NV | 239.72 Million EUR | 99.992% |
Genfit S.A. | 28.56 Million EUR | 99.931% |
GeNeuro SA | - EUR | -Infinity% |
Hyloris Pharmaceuticals SA | 2.08 Million EUR | 99.051% |
Innate Pharma S.A. | 51.9 Million EUR | 99.962% |
Inventiva S.A. | 17.47 Million EUR | 99.887% |
MaaT Pharma SA | 2.22 Million EUR | 99.111% |
MedinCell S.A. | 9.16 Million EUR | 99.784% |
Nanobiotix S.A. | 30.05 Million EUR | 99.934% |
Onward Medical N.V. | 532 Thousand EUR | 96.279% |
Oryzon Genomics S.A. | 14.19 Million EUR | 99.861% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 99.111% |
Oxurion NV | 263 Thousand EUR | 92.473% |
Pharming Group N.V. | 245.31 Million EUR | 99.992% |
Poxel S.A. | 1.98 Million EUR | 99.001% |
GenSight Biologics S.A. | 1.26 Million EUR | 98.438% |
Transgene SA | 1.18 Million EUR | 98.328% |
Financière de Tubize SA | - EUR | -Infinity% |
UCB SA | 5.25 Billion EUR | 100.0% |
Valneva SE | 153.71 Million EUR | 99.987% |
Vivoryon Therapeutics N.V. | -3.62 Million EUR | 100.547% |